Fundraising FoxVida Ventures — 2024 Investments
8 investments dated 2024 · listed companies and verified rows first · show all
Aktis Oncology discovers and develops targeted radiopharmaceuticals for treating solid tumors.
BiotechHealthtechMedical DevicesBoston, US
Todd Foley(Co-founder and Chairman)inPatrick Baeuerle(Co-founder & Advisor)inShulamit Ron-Bigger(Executive Officer)inKyle D. Kuvalanka(Chief Financial Officer)inAkos Czibere(Chief Medical Officer)inPaul L. Feldman(Chief Scientific Officer)in
Board seatHelen S. Kim· per SEC Form D
Co-investorsAndreessen HorowitzEcoR1 CapitalMPM BioImpactMRL Ventures FundPappas CapitalRA Capital+5 more
A clinical-stage biopharmaceutical company developing small molecule therapies for schizophrenia, bipolar depression, and other neuropsychiatric disorders.
BiotechHealthtechNew York, US
Zachary Prensky(Executive Officer, Director)inLauren Stipp(Executive Officer)Mark Panoff(Executive Officer)Heather Turner(President & Chief Executive Officer and Director)Gad Soffer(Chief Operating and Business Officer)Anna Eramo(Chief Medical Officer)
Co-investorsPivotal Life SciencesPontifax Venture CapitalTarnagulla VenturesTCG Crossover
InduPro develops next-generation protein therapeutics by leveraging inherent and induced proximity to modulate disease biology, with a focus on ADCs and T-cell engagers.
BiotechDeep TechMedical DevicesSeattle, US
K. Chris Garcia(Scientific Founder)Prakash Raman(CEO)inAmanda J. Redig(Chief Medical Officer)inScott Lesley(President & CSO)inPamela Holland(SVP of Biology)inSally Johnson(Chief People Officer)in
Co-investorsMRL Ventures FundThe Column Group
Iconovir is a biotechnology company focused on developing cancer treatments, with a stated mission to cure cancer and restore life to patients.
BiotechHealthtechNew York, US
Sean Algeo(Executive Officer, Promoter)inMark A. McCamish(Executive Officer, Director)inDavid M. Tanen(Executive Officer, Promoter)
BoardDavid Chang(Director, Promoter)Helen Kim(Director)Jakob Loven(Director)in
Board seatHelen S. KimJoshua KazamArie Belldegrun· per SEC Form D
Co-investorsGV (Google Ventures)Nextech InvestWellington Management
BiotechWatertown, US
Kathy Bergsteinsson(Executive Officer)inKathy Yi(Executive Officer)inJoseph Knowles(Executive Officer, Director)
BoardLucio Iannone(Director)inArjun Goyal(Director)Jill DeSimone(Director)
Co-investorsLeaps by Bayer
CandidRx develops T-cell engager antibodies to treat autoimmune diseases by redirecting T-cells to eliminate autoreactive B-cells.
BiotechHealthtechSan Diego, US
Ken Song(Chairman, President and CEO)inKenneth Song, M.D.(Executive Officer, Director)Arvind Kush(Executive Officer)Timothy Lu, M.D.(Executive Officer)inBernie Huyghe, Ph.D.(Executive Officer)
BoardJeffrey Tong, Ph.D.(Director)
Co-investorsForesite CapitalLifeSci Venture PartnersOrbiMedSamsara BioCapitalTCG CrossoverThird Rock Ventures+2 more
BiotechMedical DevicesNew Haven, US
Scott Phillips(Executive Officer)in
BoardTim Shannon(Manager)inLiam Ratcliffe(Manager)in
Co-investorsAccess BiotechnologyCanaan PartnersConnecticut InnovationsElm Street VenturesFrazier Life SciencesRA Capital+1 more
Third Arc Bio develops breakthrough treatments in oncology and immunology through advanced biologics engineering.
BiotechMedical DevicesLower Gwynedd, US
Joseph Erhardt(Executive Officer)inPeter Lebowitz(Executive Officer, Director)
BoardArjun Goyal(Director)inOtello Stampacchia(Director)inFrancesco Draetta(Director)in
Co-investorsAndreessen Horowitzabrdn plcBiotechnology Value FundForesite CapitalHillhouse InvestmentOmega Funds+1 more
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.